ClinicalTrials.gg
CompletedNCT03891524AXIOMATIC-TKRUpdated Mar 30, 2025Results posted

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

A Phase 2 interventional study of JNJ-70033093 25 mg and JNJ-70033093 50 mg in Arthroplasty, Replacement, Knee, sponsored by Janssen Research & Development, LLC. Completed at 117 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,242
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death) during the treatment period.

Read the detailed description

JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, 10 to14 day postoperative dosing phase, and 4-week follow-up phase. The hypothesis of this study is JNJ-70033093 reduces risk of total VTE during treatment period. The total duration of participation following randomization will be approximately 6 weeks. Efficacy evaluations include unilateral venography assessment of operated leg and assessments of symptomatic DVT, PE, or death. Safety evaluation includes adverse events, clinical laboratory tests, and physical examinations. The safety and efficacy will be monitored throughout the study.

02

Conditions studied

  • Arthroplasty, Replacement, Knee
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable and appropriate for anticoagulant prophylaxis as determined by the investigator on the basis of physical examination, medical history, and vital signs performed as part of screening for elective total knee replacement (TKR) surgery
  • Medically stable and appropriate for anticoagulant prophylaxis on the basis of clinical laboratory tests performed as part of local standard-of-care as part of screening for elective TKR surgery
  • Has plans to undergo an elective primary unilateral TKR surgery
  • A woman must be- a) Not of ; b) Of childbearing potential and practicing a highly effective method of (failure rate of less than [\<]1 percent [%] per year when used consistently and correctly) and agrees to remain on a highly effective method for the duration of study drug with JNJ-70033093 plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle) for a total of 34 days after the completion of treatment, pregnancy testing (serum or urine) prior to the first dose of study drug
  • Willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • History of any condition for which the use of low molecular-weight heparin (LMWH) is not recommended in the opinion of the investigator (for example, previous allergic reaction, \<30 milliliter per minute [mL/minute])
  • History of severe hepatic impairment
  • Planned bilateral revision or unicompartmental procedure
  • Unable to undergo venography (for example, due to contrast agent allergy, poor venous access, or impaired renal function that would increase the risk of contrast-induced nephropathy
  • Known previous pulmonary embolism (PE) or deep vein thrombosis (DVT) in either lower extremity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,242 participants (actual)

Study arms

  • Experimental
    Group A: JNJ-70033093 25 mg + Placebo BID

    Participants will receive JNJ-70033093 25 milligram (mg) (1\*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 25 mg · Drug: Placebo

  • Experimental
    Group B: JNJ-70033093 50 mg BID

    Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 50 mg

  • Experimental
    Group C: JNJ-70033093 100 mg + Placebo BID

    Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 100 mg · Drug: Placebo

  • Experimental
    Group D: JNJ-70033093 200 mg BID

    Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 200 mg

  • Experimental
    Group E: JNJ-70033093 25 mg Once Daily + Placebo

    Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 25 mg · Drug: Placebo

  • Experimental
    Group F: JNJ-70033093 200 mg Once Daily + Placebo

    Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 200 mg · Drug: Placebo

  • Experimental
    Group G: JNJ-70033093 50 mg once daily + Placebo

    Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.

    Drug: JNJ-70033093 50 mg · Drug: Placebo

  • Active comparator
    Group I: Enoxaparin 40 mg Once Daily

    Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.

    Drug: Enoxaparin 40 mg

Interventions

  • Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.

    Also known as: BMS-986177

  • Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.

    Also known as: BMS-986177

  • Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.

    Also known as: BMS-986177

  • Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.

    Also known as: BMS-986177

  • DrugPlacebo

    Participants will receive placebo matching to JNJ-70033093, orally.

  • Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)

    Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.

    Time frame: Up to Day 14

Secondary outcomes

  1. Number of Participants With Any Bleeding Event (CEC-adjudicated)

    Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC.

    Time frame: Up to Day 14; Up to Day 52

  2. Number of Participants With Total VTE (CEC-adjudicated)

    Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death.

    Time frame: Up to Day 52

  3. Number of Participants With Composite of Major and Clinically Relevant Nonmajor Bleeding (CRNM) Events (CEC-adjudicated)

    Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma.

    Time frame: Up to Day 14, Up to Day 52

  4. Number of Participants With Major Bleeding Events (CEC-adjudicated)

    Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability.

    Time frame: Up to Day 14; Up to Day 52

  5. Number of Participants With CRNM Bleeding Events (CEC-adjudicated)

    Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

    Time frame: Up to Day 14; Up to Day 52

  6. Number of Participants With Minimal Bleeding Events (CEC-adjudicated)

    Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

    Time frame: Up to Day 14; Up to Day 52

  7. Number of Participants With Major or CRNM Bleeding Events (CEC-adjudicated)

    Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

    Time frame: Up to Day 14; Up to Day 52

  8. Number of Participants With Major VTE (CEC-adjudicated)

    Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.

    Time frame: Up to Day 52

  9. Number of Participants With Major VTE (CEC-adjudicated)

    Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.

    Time frame: Up to Day 14

  10. Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)

    Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

    Time frame: Up to Day 14

  11. Number of Participants With Proximal DVT (CEC-adjudicated)

    Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

    Time frame: Up to Day 52

  12. Number of Participants With Distal DVT (CEC-adjudicated)

    Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

    Time frame: Up to Day 14

  13. Number of Participants With Distal DVT (CEC-adjudicated)

    Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

    Time frame: Up to Day 52

  14. Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)

    Number of participants with nonfatal PE (adjudicated by CEC) were reported.

    Time frame: Up to Day 14

  15. Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)

    Number of participants with nonfatal PE (adjudicated by CEC) were reported.

    Time frame: Up to Day 52

  16. Number of Participants With Deaths (CEC-adjudicated)

    Number of participants with deaths (CEC-adjudicated) were reported.

    Time frame: Up to Day 14

  17. Number of Participants With Deaths (CEC-adjudicated)

    Number of participants with deaths (CEC-adjudicated) were reported.

    Time frame: Up to Day 52

  18. Apparent Clearance (CL/F) of JNJ-70033093

    Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Up to Day 14

  19. Apparent Volume of Distribution (V/F) of JNJ-70033093

    V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.

    Time frame: Up to Day 14

  20. Impact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex

    Impact of demographic character (sex) on CL/F was assessed.

    Time frame: Up to Day 14

  21. Impact of Selected Demographic: Age on CL/F

    Impact of age on CL/F was assessed.

    Time frame: Up to Day 14

  22. Impact of Selected Demographic: Weight on CL/F

    Impact of weight on CL/F was assessed.

    Time frame: Up to Day 14

  23. Impact of Selected Laboratory Values: Renal Function on CL/F

    Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL.

    Time frame: Up to Day 14

  24. Impact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F)

    Impact of sex on V/F was assessed.

    Time frame: Up to Day 14

  25. Impact of Selected Demographics : Age on V/F

    Impact of age on V/F was assessed.

    Time frame: Up to Day 14

  26. Impact of Selected Demographics : Weight on V/F

    Impact of weight on V/F was assessed.

    Time frame: Up to Day 14

  27. Impact of Selected Laboratory Values: Renal Function on V/F

    Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL.

    Time frame: Up to Day 14

  28. Trend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach

    The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.

    Time frame: Up to 14 days

  29. Trend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach

    The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.

    Time frame: Up to 14 days

07

Results

Posted Jul 15, 2022

Participant flow

Participant flow — Overall Study
MilestoneJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Started34150153150149152153301
Safety analysis set33150148148147149148296
Completed34149151149147150151299
Not completed01212222
Withdrew: Death00000001
Withdrew: Withdrawal by subject01212221

Outcome measures

PrimaryNumber of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)

Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)73027148121054
SecondaryNumber of Participants With Any Bleeding Event (CEC-adjudicated)

Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC.

Time frame:
Up to Day 14; Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Any Bleeding Event (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 140827117612
Up to Day 520827117612
SecondaryNumber of Participants With Total VTE (CEC-adjudicated)

Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Total VTE (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Total VTE (CEC-adjudicated)73027148121054
SecondaryNumber of Participants With Composite of Major and Clinically Relevant Nonmajor Bleeding (CRNM) Events (CEC-adjudicated)

Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma.

Time frame:
Up to Day 14, Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Composite of Major and Clinically Relevant Nonmajor Bleeding (CRNM) Events (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 1402021115
Up to Day 5202022115
SecondaryNumber of Participants With Major Bleeding Events (CEC-adjudicated)

Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability.

Time frame:
Up to Day 14; Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Major Bleeding Events (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 1400000001
Up to Day 5200000001
SecondaryNumber of Participants With CRNM Bleeding Events (CEC-adjudicated)

Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

Time frame:
Up to Day 14; Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With CRNM Bleeding Events (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 1402021114
Up to Day 5202022114
SecondaryNumber of Participants With Minimal Bleeding Events (CEC-adjudicated)

Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

Time frame:
Up to Day 14; Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Minimal Bleeding Events (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 1406258748
Up to Day 5206259758
SecondaryNumber of Participants With Major or CRNM Bleeding Events (CEC-adjudicated)

Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

Time frame:
Up to Day 14; Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Major or CRNM Bleeding Events (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Up to Day 1402021115
Up to Day 5202022115
SecondaryNumber of Participants With Major VTE (CEC-adjudicated)

Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Major VTE (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Major VTE (CEC-adjudicated)02110204
SecondaryNumber of Participants With Major VTE (CEC-adjudicated)

Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Major VTE (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Major VTE (CEC-adjudicated)02110204
SecondaryNumber of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)

Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Asymptomatic00000001
Symptomatic00000000
SecondaryNumber of Participants With Proximal DVT (CEC-adjudicated)

Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Proximal DVT (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Asymptomatic00000001
Symptomatic00000000
SecondaryNumber of Participants With Distal DVT (CEC-adjudicated)

Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Distal DVT (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Asymptomatic72726138101050
Symptomatic02000100
SecondaryNumber of Participants With Distal DVT (CEC-adjudicated)

Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Distal DVT (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Asymptomatic72726138101050
Symptomatic02200100
SecondaryNumber of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)

Number of participants with nonfatal PE (adjudicated by CEC) were reported.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)00010101
SecondaryNumber of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)

Number of participants with nonfatal PE (adjudicated by CEC) were reported.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)00010101
SecondaryNumber of Participants With Deaths (CEC-adjudicated)

Number of participants with deaths (CEC-adjudicated) were reported.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Deaths (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Deaths (CEC-adjudicated)00000001
SecondaryNumber of Participants With Deaths (CEC-adjudicated)

Number of participants with deaths (CEC-adjudicated) were reported.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Number of Participants With Deaths (CEC-adjudicated)
ParticipantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Number of Participants With Deaths (CEC-adjudicated)00000001
SecondaryApparent Clearance (CL/F) of JNJ-70033093

Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Clearance (CL/F) of JNJ-70033093
Liter per hour (L/h)Overall
Apparent Clearance (CL/F) of JNJ-700330937.72 ± 39.5
SecondaryApparent Volume of Distribution (V/F) of JNJ-70033093

V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (V/F) of JNJ-70033093
LiterOverall
Apparent Volume of Distribution (V/F) of JNJ-70033093125 ± 60.5
SecondaryImpact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex

Impact of demographic character (sex) on CL/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liter per hour (L/h)
Impact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex
Liter per hour (L/h)FemaleMale
Impact of Selected Demographics: Apparent Clearance (CL/F) Based on Sex7.14 ± 38.59.32 ± 34.2
SecondaryImpact of Selected Demographic: Age on CL/F

Impact of age on CL/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · L/h
Impact of Selected Demographic: Age on CL/F
L/hAge: Less Than or Equal to (<=) 68 YearsAge: Greater Than (>) 68 Years
Impact of Selected Demographic: Age on CL/F8.70 ± 36.96.83 ± 37.7
SecondaryImpact of Selected Demographic: Weight on CL/F

Impact of weight on CL/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · L/h
Impact of Selected Demographic: Weight on CL/F
L/hWeight: <= 82 Kilograms (kg)Weight: Greater Than (>) 82 kg
Impact of Selected Demographic: Weight on CL/F7.04 ± 37.98.54 ± 38.4
SecondaryImpact of Selected Laboratory Values: Renal Function on CL/F

Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL.

Time frame:
Up to Day 14
Reported as:
Geometric mean · L/h
Impact of Selected Laboratory Values: Renal Function on CL/F
L/hCreatinine Clearance (CRCL): Less Than (<) 90CRCL: Greater Than or Equal to (>=) 90
Impact of Selected Laboratory Values: Renal Function on CL/F6.71 ± 38.18.83 ± 35.1
SecondaryImpact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F)

Impact of sex on V/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liters
Impact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F)
LitersFemaleMale
Impact of Selected Demographics: Sex on Apparent Volume of Distribution (V/F)118 ± 61.2143 ± 56.0
SecondaryImpact of Selected Demographics : Age on V/F

Impact of age on V/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liters
Impact of Selected Demographics : Age on V/F
LitersAGE <= 68 YearsAGE >68 Years
Impact of Selected Demographics : Age on V/F135 ± 59.5116 ± 60.3
SecondaryImpact of Selected Demographics : Weight on V/F

Impact of weight on V/F was assessed.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liters
Impact of Selected Demographics : Weight on V/F
LitersWeight <= 82kgWeight > 82kg
Impact of Selected Demographics : Weight on V/F109 ± 58.8145 ± 57.5
SecondaryImpact of Selected Laboratory Values: Renal Function on V/F

Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL.

Time frame:
Up to Day 14
Reported as:
Geometric mean · Liters
Impact of Selected Laboratory Values: Renal Function on V/F
LitersCRCL < 90CRCL >= 90
Impact of Selected Laboratory Values: Renal Function on V/F116 ± 62.2135 ± 58.5
SecondaryTrend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach

The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.

Time frame:
Up to 14 days
Reported as:
Number · proportion of participants
Trend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach
proportion of participantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BID
Trend Test for Primary Efficacy Event Rate (CEC Adjudicated) by Multiple Comparison Procedure - Modelling (MCP-Mod) Approach0.35 (0.17 to 0.52)0.21 (0.16 to 0.25)0.20 (0.15 to 0.24)0.13 (0.10 to 0.16)0.09 (0.07 to 0.12)0.09 (0.06 to 0.11)0.07 (0.03 to 0.10)
Statistical analysis
  • JNJ-70033093 25 mg + Placebo Twice Daily (BID) vs JNJ-70033093 50 mg BID vs JNJ-70033093 100 mg + Placebo BID vs JNJ-70033093 200 mg BID · MCP-mod analysis · p = 0.0004
SecondaryTrend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach

The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate.

Time frame:
Up to 14 days
Reported as:
Number · proportion of participants
Trend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach
proportion of participantsJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BID
Trend Test for the Composite of On-Treatment Major and Clinically Relevant Nonmajor Bleeding (CEC Adjudicated) by MCP-Mod Approach0.02 (0.00 to 0.17)0.01 (0.00 to 0.03)0.01 (0.00 to 0.04)0.01 (0.00 to 0.02)0.01 (0.00 to 0.02)0.01 (0.00 to 0.02)0.01 (0.00 to 0.02)
Statistical analysis
  • JNJ-70033093 25 mg + Placebo Twice Daily (BID) vs JNJ-70033093 50 mg BID vs JNJ-70033093 100 mg + Placebo BID vs JNJ-70033093 200 mg BID · MCP-MOD analysis · p = 0.7188

Adverse events

Collected over Up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JNJ-70033093 25 mg Once Daily + Placebo0/33 (0%)1/33 (3%)0/33 (0%)
JNJ-70033093 50 mg Once Daily + Placebo0/150 (0%)2/150 (1.3%)6/150 (4%)
JNJ-70033093 25 mg + Placebo Twice Daily (BID)0/148 (0%)5/148 (3.4%)9/148 (6.1%)
JNJ-70033093 50 mg BID0/148 (0%)5/148 (3.4%)8/148 (5.4%)
JNJ-70033093 200 mg Once Daily + Placebo0/147 (0%)2/147 (1.4%)3/147 (2%)
JNJ-70033093 100 mg + Placebo BID0/149 (0%)5/149 (3.4%)4/149 (2.7%)
JNJ-70033093 200 mg BID0/148 (0%)2/148 (1.4%)3/148 (2%)
Enoxaparin 40 mg Once Daily1/296 (0.3%)11/296 (3.7%)17/296 (5.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
Deep Vein ThrombosisVascular disorders1/331/1501/1481/1480/1472/1490/1480/296
VomitingGastrointestinal disorders0/330/1500/1480/1481/1470/1490/1480/296
Cardiovascular EvaluationInvestigations0/330/1500/1480/1481/1470/1490/1480/296
Atrial FibrillationCardiac disorders0/330/1501/1480/1480/1470/1490/1480/296
Non-Cardiac Chest PainGeneral disorders0/330/1501/1480/1480/1470/1490/1480/296
UrosepsisInfections and infestations0/330/1501/1480/1480/1470/1490/1480/296
ContusionInjury, poisoning and procedural complications0/330/1500/1481/1480/1470/1490/1480/296
Periprosthetic FractureInjury, poisoning and procedural complications0/330/1500/1481/1480/1470/1490/1480/296
ArthralgiaMusculoskeletal and connective tissue disorders0/330/1500/1480/1480/1470/1491/1480/296
Compartment SyndromeMusculoskeletal and connective tissue disorders0/330/1500/1481/1480/1470/1490/1480/296
Most frequent other events
Most frequent other events
EventJNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once Daily
ConstipationGastrointestinal disorders0/336/1509/1488/1483/1474/1493/14817/296

Baseline characteristics

Age, Continuous
Age, Continuous(years)JNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once DailyTotal
Mean68.1 ± 5.7467.9 ± 8.0368.4 ± 8.4968.8 ± 8.1768 ± 8.2567 ± 868.6 ± 7.7667.8 ± 7.9768 ± 8.02
Sex: Female, Male
Sex: Female, Male(Participants)JNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once DailyTotal
Female24107113108108102106208876
Male1043404241504793366
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once DailyTotal
Hispanic or Latino621192020141442156
Not Hispanic or Latino281211261251251291332501037
Unknown or Not Reported0885496949
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once DailyTotal
American Indian or Alaska Native000010012
Asian022171617161632136
Native Hawaiian or Other Pacific Islander000110024
Black or African American0121031412
White341241341321291321362601081
More than one race000010001
Unknown or Not Reported030001026
Region of Enrollment
Region of Enrollment(Participants)JNJ-70033093 25 mg Once Daily + PlaceboJNJ-70033093 50 mg Once Daily + PlaceboJNJ-70033093 25 mg + Placebo Twice Daily (BID)JNJ-70033093 50 mg BIDJNJ-70033093 200 mg Once Daily + PlaceboJNJ-70033093 100 mg + Placebo BIDJNJ-70033093 200 mg BIDEnoxaparin 40 mg Once DailyTotal
Asia022161616161632134
Europe21556565646465129528
South America09767761355
North America519201919192138160
Western Europe845454443464589365
08

Study locations

117 sites
  • Central Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Bowen Hefley Orthopedics
    Little Rock, Arkansas 72205, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Denver Metro Orthopedics, PC
    Englewood, Colorado 80113, United States
  • DMI Research
    Pinellas Park, Florida 33782, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • University Orthopedic and Joint Replacement Center
    Tamarac, Florida 33321, United States
  • Memorial Hermann Memorial City Medical Center
    Houston, Texas 77024, United States
  • Clinica Adventista Belgrano
    Caba, C1430EGF, Argentina
  • Hospital Britanico de Buenos Aires
    Ciudad Autonoma de Buenos Aires, C1280AEB, Argentina
  • Hospital San Roque
    Córdoba, 5000, Argentina
  • Clínica Chutro
    Córdoba, X5000EPU, Argentina
  • Hospital Italiano La Plata
    La Plata, B1900AXI, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, S2000BIF, Argentina
  • Sanatorio Corporación Médica de General San Martín
    San Martín, B1650BNB, Argentina
  • ZNA Middelheim
    Antwerpen, 2020, Belgium
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • Hospital Sao Francisco de Assis
    Belo Horizonte, 30360-290, Brazil
  • Hospital e Maternidade Dr Christovao da Gama S.A
    Santo Andre, 09030-010, Brazil
  • Hospital Estadual Mario covas
    Santo André, 09190-615, Brazil
  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski
    Pleven, 5800, Bulgaria
  • Acibadem City Clinic Tokuda Hospital
    Sofa, 1407, Bulgaria
  • University Multiprofile Hospital Sofiamed Sofia
    Sofia, 1330, Bulgaria
  • MHAT Tzaritza Joanna
    Sofia, 1527, Bulgaria
  • Medical Center - Medical Complex BEROE EOOD
    Stara Zagora, 6000, Bulgaria
  • Lakeridge Health
    Ajax, Ontario L1S 2J4, Canada
  • Hamilton Health Sciences Corporation
    Hamilton, Ontario L8V1C3, Canada
  • The Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Medical Investigative and Clinical Evaluation Inc
    Windsor, Ontario N8W 1E6, Canada
  • General Hospital of Attiki 'KAT'
    Kifisia, 14561, Greece
  • General Hospital of Nea Ionia 'Konstantopoulio'
    Nea Ionia, 14233, Greece
  • University General Hospital of Rio Patras
    Patras, 26504, Greece
  • Papageorgiou General Hospital
    Thessaloniki, 56403, Greece
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyõr, 9023, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Bacs-kiskun Megyei Korhaz
    Kecskemét, 6000, Hungary
  • Szegedi Tudomanyegyetem
    Szeged, 6725, Hungary
  • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
    Szekesfehervar, 8000, Hungary
  • MAV Korhaz es Rendelointezet
    Szolnok, 5000, Hungary
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Meir Medical Center
    Kfar Saba, 44281, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Cliniche Humanitas Gavazzeni
    Bergamo, 24125, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
  • Policlinico S. Matteo
    Pavia, 27100, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • A.O.U. Città della Salute e della Scienza
    Torino, 10126, Italy
  • Matsudo City General Hospital
    Chiba, 270-2296, Japan
  • Hakodate Goryoukaku Hospital
    Hakodate, 040 8611, Japan
  • Japanese Red Cross Hamamatsu Hospital
    Hamamatsu, 434-8533, Japan
  • Itami City Hospital
    Itami-shi, 664-8540, Japan
  • Yonemori Hospital
    Kagoshima-shi, 890-0062, Japan
  • Japan Community Health care Organization Kyushu Hospital
    Kitakyushu-shi, 806-8501, Japan
  • Marunouchi Hospital
    Matsumoto, 390-8601, Japan
  • Chubu Rosai Hospital
    Nagoya, 455-8530, Japan
  • Juntendo University Nerima Hospital
    Nerima-Ku, 177-8521, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, 701-1192, Japan
  • Yuuai Medical Center
    Okinawa, 901-0224, Japan
  • Saitama City Hospital
    Saitama-shi, 336-8522, Japan
  • Japan Community Health Care Organization Saitama Medical Center
    Saitama, 350-8550, Japan
  • Nagano Prefectural Shinshu Medical Center
    Suzaka, 386-8610, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Bielsku Podlaskim Oddzial Urazowo Ortopedyczny
    Bielsk Podlaski, 17 100, Poland
  • Szpital Ogolny im. W. Ginela, Oddzial Urazowo-Ortopedyczny
    Grajewo, 19-200, Poland
  • Wojewodzki Szpital Zespolony w Kielcach, Klinika Chirurgii Ortopedyczno-Urazowej
    Kielce, 25-001, Poland
  • Oddzial Ortopedii i Traumatologii Narzadu Ruchu Szpital Specjalistyczny im Ludwika Rydygiera
    Krakow, 31 826, Poland
  • CSK UM Klinika Ortopedii
    Lodz, 92-213, Poland
  • Oddzial Urazowo-Ortopedyczny Wojewodzki Szpital Specjalistyczny
    Lublin, 20-718, Poland
  • Oddzial Ortopedii Specjalistyczny Szpital im. E.Szczeklika
    Tarnow, 33-100, Poland
  • Oddzial Chirurgii Urazowej iOrtopedycznej Wojewodzki Szpital Brodnowski SPZOZ
    Warszawa, 03 242, Poland
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
    Wroclaw, 50 556, Poland
  • Centro Hospitalar do Baixo Vouga - Hospital Infante Dom Pedro
    Aveiro, 3810-501, Portugal
  • Hosp de Cascais
    Cascais, 2755-009, Portugal
  • H. Santo António - Centro Hospitalar do Porto
    Porto, 4099-001, Portugal
  • CHS - Hosp. Orto. Sant'Iago do Outao
    Setubal, 2900-180, Portugal
  • ULSAM, EPE - Hospital de Santa Luzia
    Viana do Castelo, 4904-858, Portugal
  • National Medical Research Center of Traumatology and Orthopaedics n.a. G.A. Ilizarov
    Kurgan, 640014, Russian Federation
  • Private Healthcare Institution 'Clinical Hospital 'RZD-Medcine' n.a. N.A.Semashko'
    Moscow, 109386, Russian Federation
  • Privolzhsky Regional Medical Center of Federal Medical and Biological Agency
    Nizhniy Novgorod, 603137, Russian Federation
  • National medical research center of Traumatology and Orthopaedics n.a. R.R.Vreden
    Saint-Petersburg, 195427, Russian Federation
  • State Healthcare Institution Samara Regional Clinical Hospital named after V.D.Seredavin
    Samara, 443095, Russian Federation
  • Smolensk Federal Center of Traumatology, Orthopedics and Endoprothesis Replacement
    Smolensk, 214031, Russian Federation
  • Sochi City Hospital #4
    Sochi, 354057, Russian Federation
  • Steve Biko Academic Hospital
    Pretoria, 0001, South Africa
  • Clinical Project Research SA
    Worcester, 6850, South Africa
  • Hosp. Univ. Fundacion Alcorcon
    Alcorcón, 28922, Spain
  • Hosp. Univ. Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hosp. Univ. de Bellvitge
    Barcelona, 08907, Spain
  • Hosp Univ Vall D Hebron
    Barcelona, 8035, Spain
  • Complejo Hospitalario de Jaen
    Jaen, 23007, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp. Univ. La Paz
    Madrid, 28046, Spain

Showing the first 100 of 117 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE; AXIOMATIC-TKR Investigators. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 Dec 2;385(23):2161-2172. doi: 10.1056/NEJMoa2113194. Epub 2021 Nov 15. PubMed 34780683 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinicaltrials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Apr 2021, 21 months.

Results were first posted in Jul 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 27, 2019
StartActual
Jun 17, 2019
Primary completionActual
Apr 6, 2021
CompletionActual
Apr 6, 2021
Results first posted
Jul 15, 2022
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03891524
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Jun 17, 2019
Primary completion
Apr 6, 2021
Completion
Apr 6, 2021
Results posted
Jul 15, 2022
Last update
Mar 30, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion